Sprouts Farmers Market closes $600 million revolving credit facility
Cantor Fitzgerald maintained its Overweight rating and $13.00 price target on Taysha Gene Therapies (NASDAQ:TSHA) this week, with the stock currently trading at $2.67 and showing impressive YTD gains of 54%. The firm’s assessment follows attendance at the IRSF Rett Syndrome Scientific Meeting, where Cantor representatives also met with Taysha management.
The rating reaffirmation comes after Taysha’s recent positive Phase 1/2 data and regulatory update regarding its AAV-based gene therapy, TSHA-102, which is being developed to treat Rett syndrome. The data presented at the IRSF meeting was an encore presentation of previously released results. According to InvestingPro data, analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $5 to $13.
Cantor Fitzgerald noted strong positive sentiment toward Taysha’s developments among various stakeholders at the conference, including investors and key opinion leaders in the field.
Despite this favorable reception, Cantor observed that the positive outlook has not translated to Taysha’s current market valuation. The firm specifically stated, "Sentiment across the conference was very positive, but we don’t think that has been reflected in TSHA’s valuation today."
The maintained $13.00 price target suggests significant potential upside for the gene therapy company as it continues development of its Rett syndrome treatment candidate.
In other recent news, Taysha Gene Therapies has made significant strides in its development of TSHA-102, a gene therapy for Rett syndrome. The company has received FDA alignment for a pivotal trial design, expected to begin in the third quarter of 2025, which will focus on developmental milestone gains in patients. All patients in the REVEAL Part A trial achieved at least one developmental milestone, with no serious adverse events reported. Analysts from Citizens JMP responded by raising the price target to $6.00 and maintaining a Market Outperform rating, citing the positive trial design and FDA alignment.
Additionally, Canaccord Genuity raised its price target for Taysha Gene Therapies to $11, reflecting increased confidence in the TSHA-102 program. The firm noted a higher probability of success for the therapy and acknowledged the company’s $200 million offering through shares and prefunded warrants. Meanwhile, Cantor Fitzgerald reiterated a $7.00 target, emphasizing the significance of new data and the outlined regulatory pathway for TSHA-102.
In corporate developments, Taysha’s stockholders approved an amendment to increase authorized shares to 700 million. The company also announced the election of two directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm. These recent developments underscore Taysha Gene Therapies’ ongoing efforts to advance its gene therapy pipeline and support its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.